Subcellular distribution and glycosylation pattern of androgen receptor from sheep omental adipose tissue

G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis

Obesity and its related metabolic diseases have reached a pandemic level worldwide. There are sex differences in the prevalence of obesity and its related metabolic diseases, with men being more vulnerable than women; however, the prevalence of these disorders increases dramatically in women after menopause, suggesting that sex steroid hormone estrogens play key protective roles against development of obesity and metabolic diseases. Estrogens are important regulators of several aspects of metabolism, including body weight and body fat, caloric intake and energy expenditure, and glucose and lipid metabolism in both males and females. Estrogens act in complex ways on their nuclear estrogen receptors (ERs) ERα and ERβ and transmembrane ERs such as G protein-coupled estrogen receptor. Genetic tools, such as different lines of knockout mouse models, and pharmacological agents, such as selective agonists and antagonists, are available to study function and signaling mechanisms of ERs. We provide an overview of the evidence for the physiological and cellular actions of ERs in estrogen-dependent processes in the context of energy homeostasis and body fat regulation and discuss its pathology that leads to obesity and related metabolic states.

Evidence Denies the Presence of O-GlcNAcylation on Mouse Glucocorticoid Receptor and Its Potential Involvement in Receptor Transcriptional Activity

O-linked N-acetylglucosamine (GlcNAc) glycosylation (O-GlcNAcylation) is commonly found on many cytoplasmic and nuclear proteins. It can play a role in protein trafficking, signal transduction, and in some nuclear proteins it is involved in the control of gene expression. The steroid receptor family consists of proteins that have similar domain architecture including individual DNA and hormone-binding domains that have closely related three-dimensional structures. The discovery of O-linked GlcNAc on both androgen and estrogen receptors and the realization that the GlcNAc plays a role in the transcriptional activity of these receptors raise the possibility that this glycosylation is a common mechanism involved in transcriptional modulation in all members of the steroid receptor family. To test this hypothesis, we affinity purified the mouse glucocorticoid receptor from cell lines engineered to overexpress the receptor and used GlcNAc-specific lectin chromatography, lectin-blotting analysis, and galactosylation assay to assess the presence of GlcNAc modification. All three techniques were found to be highly sensitive when used with proteins known to harbor GlcNAc yet they failed to show the presence of GlcNAcylation on the mouse GR. We also determined the effect of mutation at seven major potential glycosylation sites of the receptor on its transcriptional activity. We conclude that either the mouse GR is not modified by GlcNAc or that the amount of the modification is so low that it cannot be detected. Therefore, the O-GlcNAcylation appears not to be a common mechanism used to modify the activity of all steroid receptors.

Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta-cell in type 1 diabetes mellitus

Androgen receptor (AR) mediates a wide range of cellular processes, such as proliferation, differentiation and apoptosis. Here we sought to identify whether AR was located in pancreatic beta-cells and investigate its functions in type 1 diabetes induced by multiple low doses of streptozotocin. Double/triple immunofluorescence, Western blot and semi-quantitative RT-PCR were carried out to determine variances of AR expression in beta-cells and correlation between AR and apoptosis/proliferation of beta-cells with progress of diabetes. In addition, in vitro primary beta-cells from control mice were cultured for 3 days or 6 days with compound stimulation in order to further identify effect of AR on beta-cell apoptosis and proliferation. AR expression in beta-cells peaked in control and 1-day diabetic mice, gradually and significantly decreased, even disappeared in diabetic mice with progress of diabetes. TUNEL-positive beta-cells were concomitant with overexpression of AR, and Ki67-positive beta-cells showed extremely weak, even negative AR staining. In vitro, AR could mediate beta-cell apoptosis, and AR antagonist flutamide contributed to beta-cell proliferation. In conclusion, AR is abundantly expressed in pancreatic beta-cell cytoplasm of control mice. With progress of type 1 diabetes, decrement of AR expression in diabetic mice contributes to prohibit beta-cells from apoptosis, and is strongly associated with beta-cell proliferation.

Expression of androgen receptor and its co-localization with estrogen receptor-alpha in the developing pituitary gland of sheep fetus

No information is known concerning the expression of androgen receptor (AR) and its co-localization with estrogen receptor alpha (ERalpha) in the developing pituitary of sheep fetus. In the present study, we detected AR expression and its co-localization with ERalpha in the anterior pituitary of sheep fetus from day 60 of gestation to the postnatal by dual immunochemistry. The results showed that both AR immunoreactivity (AR-ir) and ERalpha immunoreactivity (ERalpha-ir) were predominantly localized in the nuclei of LH positive gonadotropes. The cell counting results showed that the percentage of the anterior pituitary cells expressing AR fluctuated from 13.51 +/- 0.92 to 17.05 +/- 1.83% during the examined stages, but there were no significant differences between sexes and among ages examined (P > 0.05). However, the proportion of AR-ir cells containing LH markedly increased from day 60 of gestation to the neonatal (P < 0.05). The percentage of AR-ir cells expressing ERalpha-ir significantly increased from day 60 of gestation to the neonatal, respectively (P < 0.05), but no significant differences were seen between genders at each stage examined. These results indicate that both AR and ERalpha are mainly expressed in the gonadotropes of anterior pituitary gland of sheep fetuses, whereas the functions and interaction of AR and ERalpha expressions in the developing pituitary gland are required to be elucidated further.

Oral contraceptives and skin cancer: is there a link?

The skin expresses estrogen, progesterone, and androgen receptors. In the presence of steroid hormones, such as those contained in oral contraceptives, the skin likely responds to hormonal signals that control the cell cycle, apoptosis, DNA replication, and other cellular functions. Some estrogen-responsive pathways have the potential to promote tumor development, including the augmentation of epidermal growth factor signaling, the expression of proto-oncogenes, and inhibition of apoptosis. The question of whether oral contraceptives increase the risk for the development of skin cancer, particularly melanoma, is still an area of concern. This paper reviews the available evidence, the bulk of which suggests that while the skin responds to estrogens, progestins, and androgens, these responses do not significantly increase the risk of developing skin cancer when estrogen exposure is not excessive.

Direct effects of sex steroid hormones on adipose tissues and obesity

Sex steroid hormones are involved in the metabolism, accumulation and distribution of adipose tissues. It is now known that oestrogen receptor, progesterone receptor and androgen receptor exist in adipose tissues, so their actions could be direct. Sex steroid hormones carry out their function in adipose tissues by both genomic and nongenomic mechanisms. In the genomic mechanism, the sex steroid hormone binds to its receptor and the steroid-receptor complex regulates the transcription of given genes. Leptin and lipoprotein lipase are two key proteins in adipose tissues that are regulated by transcriptional control with sex steroid hormones. In the nongenomic mechanism, the sex steroid hormone binds to its receptor in the plasma membrane, and second messengers are formed. This involves both the cAMP cascade and the phosphoinositide cascade. Activation of the cAMP cascade by sex steroid hormones would activate hormone-sensitive lipase leading to lipolysis in adipose tissues. In the phosphoinositide cascade, diacylglycerol and inositol 1,4,5-trisphosphate are formed as second messengers ultimately causing the activation of protein kinase C. Their activation appears to be involved in the control of preadipocyte proliferation and differentiation. In the presence of sex steroid hormones, a normal distribution of body fat exists, but with a decrease in sex steroid hormones, as occurs with ageing or gonadectomy, there is a tendency to increase central obesity, a major risk for cardiovascular disease, type 2 diabetes and certain cancers. Because sex steroid hormones regulate the amount and distribution of adipose tissues, they or adipose tissue-specific selective receptor modulators might be used to ameliorate obesity. In fact, hormone replacement therapy in postmenopausal women and testosterone replacement therapy in older men appear to reduce the degree of central obesity. However, these therapies have numerous side effects limiting their use, and selective receptor modulators of sex steroid hormones are needed that are more specific for adipose tissues with fewer side effects.